Clinical and Immunological Therapy for Solid Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 1788
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, immunotherapies for solid tumors have generated spectacular outcomes for cancer patients in clinics. Adoptive cell therapies (ACT), including using autologous tumor-infiltrating lymphocyte (TILs), TCR T-cells (TCR-engineered T cell), chimeric antigen receptor (CAR) T cells, tumor vaccines and checkpoint blockade, have emerged as the most effective treatments for solid tumors. The current challenge for solid cancer immunotherapies is that although some patients have benefited from these treatments, many cancers will still have variable responses. The purpose of this Special Issue is to understand the treatment advantages and disadvantages in order to provide exciting opportunities for effective anticancer immunotherapies for solid tumors. This Special Issue welcomes reviews, as well as original research articles, which should be submitted by 30 June 2024.
Dr. Biaoru Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TCR T cells, TIL
- CAR T cells and tumor vaccines
- immunotherapy and adoptive cell transfer
- personalized immunotherapy and genomics analysis
- T-cell homing which includes T-cell rolling, adhesion, extravasation, and chemotaxis into the solid tumor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
